drug

Cognitive retraining

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
BEHAVIORAL
Pre-approval / investigational in the US
Developed by Yale University
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
BEHAVIORAL

Indications

Trials

1
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
NCT00237848Phase 3Completed

KOLs & investigators

1
Deepak Cyril D'Souza, MDKOL score 7

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Yale University
company
trial
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
PHASE3
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Deepak Cyril D'Souza, MD
KOL score 7
person